Phathom Pharmaceuticals, Inc. (PHAT )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol PHAT
- Company Phathom Pharmaceuticals, Inc.
- Price $4.22
- Changes Percentage -15.6
- Change -0.78
- Day Low $4.19
- Day High $5.05
- Year High $19.71
- Year Low $4.19
- Market Cap $293,868,140
- Price Avg 50 EMA (D) $6.16
- Price Avg 200 EMA (D) $11.17
- Exchange NASDAQ
- Volume 1,421,606
- Average Volume 1,080,600
- Open $4.99
- Previous Close $5
- EPS -5.29
- PE -0.80
- Earnings Announcement 2025-05-07 12:30:00
- Shares Outstanding $69,637,000
Company brief: PHATHOM PHARMACEUTICALS, INC. (PHAT )
- Healthcare
- Biotechnology
- Ms. Terrie J. Curran
- https://www.phathompharma.com
- US
- N/A
- 10-25-2019
- US71722W1071
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.